Sign Up For Updates
Sign up for updates
Join our mailing list to receive updates from the Drug Pricing Lab.
Thank you for signing up to receive news and information from the Drug Pricing Lab.
Return to Previous Page
The "Netflix Model" of Financing Hepatitis C Treatment
In a new piece in JAMA, Dr. Peter B. Bach, Sen. Bill Cassidy (R-LA) and Dr. Mark Trusheim outline an alternative payment model for HCV treatment - The "Netflix Model".
Journal of the American Medical Association
October 29, 2018
Copay Assistance: the Epipen example
The DPL uses a real world example of a patient's utilization of Mylan's copay coupon for Epipens to demonstrate the effects of such programs.
Drug Pricing Lab
June 6, 2017
Rebates in Medicare Part D
Read our newest research on Part D benefit design showing that rebates actually increase patients' out of pocket costs while also shifting spending from plan sponsors and manufacturers to Medicare
Drug Pricing Lab
May 30, 2017
Copay assistance: Doing more harm than good?
Dr. Peter Bach discusses how copay assistance programs are actually causing drug prices to rise on Closing Bell.
October 12, 2016
Copay Assistance for Expensive Drugs
Dr. Bach argues drug company copay and coupon programs actually play a significant role in keeping prescription drug costs in the U.S. high
Evidence Driven Drug Pricing Project
October 10, 2016
Medicare considers overhaul of doctors’ payments for drugs
Medicare officials proposed Tuesday to test new ways of reimbursing doctors who administer drugs in their offices and hospital outpatient clinics
The Washington Post
March 8, 2016
How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And Reimbursement
Dr. Steven Pearson and Dr. Peter Bach propose a payment model for Medicare that utilizes comparative effectiveness research, with higher payments for services that are deemed superior to alternative options.
October 10, 2010
No Results Found